Answer:
<u>d. Increases allocation to any stock that changes its corporate name</u>
<u>Explanation</u>:
This manager that does this practice is least likely to replicate performance because that is an unprofessional practice.
In most cases when there is a change in the name of a stock it indicates a red signal that the stock price is bad and thus the company may decide to change it's name, thus the future performance of the company diminishes.
Answer:
Ending Inventory Units = 500 + 6700 - 6000 = 1200 units
Equivalent units for Material = Units completed and transferred*100% + Ending Inventory units*50% = 6000*100% + 1200*50%
= 6000 + 600 = 6600 units
Cost per equivalent unit for materials = (Beginning Material cost + Material cost incurred during the month) / Equivalent units for Material
= ($5800 + $125600) / 6600
= $19.91
Hence, third option is correct.
Answer:
all of the above
Explanation:
When outcomes are uncertain, a manger must recognise and describe the risks involved. After identifying the risks, the risks must be evaluated to determine the extent of the risk and how the risk would affect the business. After the risks have been evaluated, the risk should be managed. For example, by taking insurance.
For example, if a manager wants to purchase a machine,
the manger has to identify the risks involved : the machine can be stolen, it can injure workers or it might not produce the desired effect
The manger must then evaluate the risks. The risks can be evaluated using capital budgeting methods. e.g. NPV
The manger can manage the risk by taking out insurance
Answer:
C. applied research.
Explanation:
Once basic research has been performed, and has landed results that are relevant to an organization, the same organization can run applied research in order to find, from the basic research results, useful applications that can be put in the market.
For example, in the pharmaceutical sector, basic research in pure biology is often turned into practical application (new medications) through applied research within the pharmaceutical companies.
